Oral Creatine Augmentation to Enhance SSRI Response in Women With MDD

 

Underlying Mechanism Behind using Creatine:

  • Creatine supplementation is known to increase –> cerebral concentration of phosphocreatine.
  • Increase cerebral creatine –> causes shift in brain creatine kinase activity –> increase production of ATP from phosphocreatine.
  • This increased generation of ATP –> known to contribute to earlier and increased response to antidepressants. 

The following study done by Lyoo et al tested this hypothesis:

  • n= 52 women with MDD
  • Duration= 8-week double-blind placebo-controlled clinical trial
  • Group 1= Escitalopram + creatine (5 g/day, N=25) or
  • Group 2= Escitalopram + placebo (N=27).
  • Dose of Escitalopram= 10 mg/day for the first week and then 20 mg/day for the following 7 weeks.
  • Scale= Hamilton Depression Rating Scale (HAM-D) score.

Results of this study:

  • RESPONSE: Women who received creatine augmentation showed greater improvement of depressive symptoms as early as week 2.
  Week 2 Week 4 Week 8
Creatine (N=25) 32.0% (N=8) 68.0% (N=17) 64.0% (N=16)
Placebo (N=27) 3.7% (N=1) 29.6% (N=8)  63.0% (N=17)

 

  • REMISSION (AT WEEK 8):
Creatine 13 (52.0%)
Placebo 7 (25.9%) 

 

  • ADVERSE EVENTS: Similar in both groups- tension headache, nausea and/or vomiting, and sleep difficulties. These are likely related to the use of SSRIs.
Creatine 43.4% (36 events)
Placebo  46.4% (45 events)

 

The present results suggest that creatine augmentation with the Escitalopram, provides a promising therapeutic approach for MDD in terms of its superior efficacy, relatively good tolerability, minimal side effects, and easy attainability.

Source: Am J Psychiatry. 2012 Sep; 169(9): 937–945.

Please do post your questions or comments below. 


Dr. Harvinder Singh, M.D. (Admin)


Enroll in our online course to have access to all important clinically relevant psychiatry topics in one place.


Related Articles